Foresee Pharmaceuticals reported February consolidated revenue of NT$27.08 million, representing a 111.7% month-on-month increase. The growth was driven by a NT$19.66 million shipment of CAMCEVI (6-month depot) to U.S. distributors, supplemented by NT$7.42 million in royalties.

• Upcoming Catalysts: The 3-month depot formulation is expected to launch in the U.S. by Q4 2026, which management anticipates will further stimulate demand for the existing 6-month version.
• European Expansion: Partner Accord Healthcare has received a "Positive Opinion" from the EMA CHMP for the 3-month formulation, with final European Commission approval expected in Q2 2026.

Resource: 逸達2月營收月增逾倍 CAMCEVI銷貨與權利金挹注